Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio.
On the company’s earnings call, Chief Executive Officer John Shan
T. Rowe Price Group (NASDAQ:TROW) held its 2026 annual meeting of stockholders virtually, with Chair, CEO and President Robert Sharps presiding over the proceedings. Stockholders approved all three items presented at the meeting, according to preliminary results announced during the event.
The comp
Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q
TeraWulf (NASDAQ:WULF) said its first-quarter 2026 results reflected a business shifting from Bitcoin mining toward contracted high-performance computing, or HPC, leasing revenue, as management highlighted progress at its Lake Mariner campus and continued demand for power-backed AI infrastructure.
WW International (NASDAQ:WW), operator of WeightWatchers, reaffirmed its 2026 financial outlook after reporting first-quarter results that reflected continued pressure in its legacy behavioral subscription business, offset in part by growth in its clinical weight-management offering and higher-value
Wynn Resorts (NASDAQ:WYNN) executives said the casino operator delivered strong first-quarter results across Las Vegas and Macau while continuing to navigate geopolitical and logistical challenges tied to its planned Wynn Al Marjan resort in the United Arab Emirates.
On the company’s first-quarter
Warner Music Group (NASDAQ:WMG) reported stronger fiscal second-quarter results, with executives saying the company’s growth strategy is gaining traction across streaming, catalog monetization, distribution and cost efficiency.
On the company’s earnings call for the period ended March 31, 2026, CEO
WillScot (NASDAQ:WSC) reported first-quarter 2026 results that management said exceeded its expectations, as stronger large-project activity and rising activations helped offset continued softness in some local markets.
The company raised its full-year outlook, citing improved visibility from its o
Willdan Group (NASDAQ:WLDN) reported a stronger-than-expected start to fiscal 2026, with executives citing margin expansion, improved productivity and rising demand for energy services as key drivers behind a raised full-year outlook.
President and Chief Executive Officer Mike Bieber said the compa
Thomson Reuters (NASDAQ:TRI) executives said the company is positioned to benefit from rising compliance complexity and demand for specialized artificial intelligence tools, while pushing back on investor concerns that general-purpose AI models could erode its core legal, tax and accounting franchis
WhiteHorse Finance (NASDAQ:WHF) reported lower first-quarter earnings and a decline in net asset value as previously identified credit issues weighed on results, while management said share repurchases helped offset some of the impact through NAV accretion.
Chief Executive Officer Stuart Aronson sa
Wendy's (NASDAQ:WEN) reported first-quarter results that management said were largely in line with expectations, while acknowledging the restaurant chain remains in the early stages of a U.S. turnaround effort aimed at improving traffic, operations and franchisee economics.
Interim Chief Executive
Westrock Coffee (NASDAQ:WEST) reported sharply higher first-quarter 2026 results, with management saying the company has moved beyond a multiyear investment phase and is now operating as an integrated beverage platform.
Co-founder and Chief Executive Officer Scott Ford said the quarter marked “the
Vital Farms (NASDAQ:VITL) executives said the company’s first-quarter results and early second-quarter scanner data fell short of expectations as retail price gaps widened beyond levels the brand could sustain, prompting a reset of 2026 guidance and a series of cost and cash management actions.
Exe
Varex Imaging (NASDAQ:VREX) reported fiscal second-quarter revenue within its guidance range and said demand remained solid across its medical and industrial businesses, while management highlighted a completed debt refinancing and continued investment in advanced imaging technologies.
President an
Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade serous ovarian cancer continued to grow despite seasonal headwinds and some early commercial executi
Vertex (NASDAQ:VERX) reported first-quarter 2026 results above its guidance range and raised its full-year profitability outlook as management outlined a cost-reduction program intended to fund investments in e-invoicing, compliance and artificial intelligence.
The tax technology company posted fir
